Healthy Adult MalePhase 1NCT07853248
Tegoprazan-Aspirin Drug Interaction in Healthy Adult Male Volunteers
A Phase 1 study testing Aspirin, Tegoprazan and Tegoprazan + Aspirin in people with Healthy Adult Male, run by HK inno.N Corporation at 1 site in South Korea.
Trial summary
This Clinical Trial Aims to Evaluate the PK/PD Drug-Drug Interaction and Safety/Tolerability of Tegoprazan and Aspirin in Healthy Adult Male Volunteers. Read more about this study
- Who is it for?
- Ages 19 to 50 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Healthy Adult Male
- What is being tested?
- Aspirin, Tegoprazan and Tegoprazan + Aspirin
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 34 participants
- Where
- 1 siteSouth Korea
- Study dates
- 14 Oct 2026to 30 Apr 2027
- Phase
- Phase 1
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 50 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy male adult volunteers aged ≥19 years and ≤50 years at the time of screening
- Participants who weigh ≥50.0 kg and ≤90.0 kg at the time of screening and have a body mass index (BMI, Body Mass Index) of ≥18.5 kg/m² and ≤29.9 kg/m²
- Participants who, after receiving a sufficient explanation of and fully understanding this clinical trial, voluntarily decide to participate and provide written consent to comply with the precautions
- Participants who are determined to be negative in the Helicobacter pylori Antibody test
- Participants considered eligible for participation in this clinical trial by the investigator based on physical examination, clinical laboratory tests, medical interview, etc.
Who cannot join
- Participants who have or have a history of clinically significant hepatobiliary diseases (e.g., severe hepatic impairment or viral hepatitis), renal diseases (e.g., severe renal impairment), neurological diseases, immune system disorders, respiratory diseases, gastrointestinal diseases, endocrine disorders, hematologic or neoplastic diseases, cardiovascular diseases (e.g., cardiac failure or Torsade de pointes), urinary system disorders, psychiatric disorders (e.g., mood disorder or obsessive-compulsive disorder), sexual dysfunction, or other relevant diseases
- Participants who have a history of gastrointestinal diseases (e.g., Crohn's disease, ulcer, gastritis, gastric spasm, or gastroesophageal reflux disease) or gastrointestinal surgery (except for simple appendectomy or hernia surgery) that may affect the evaluations of the safety, pharmacokinetics, and pharmacodynamics of the investigational product
- Participants who have hypersensitivity to P-CAB (Potassium-Competitive Acid Blocker), drugs of the same class, or any other drugs (e.g., Aspirin or other salicylates, antibiotics, or benzimidazole anthelmintics), or who have a history of clinically significant hypersensitivity
- Participants with hereditary problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
- Participants with positive serology results for hepatitis B, hepatitis C, human immunodeficiency virus (HIV), or syphilis
- Participants with a history of drug abuse or who test positive for drugs of abuse in a urine drug screening test
Show all 29Show fewer
- Participants with any of the following vital sign values measured in the sitting position after at least 3 minutes of rest at screening:
- Systolic blood pressure < 80 mmHg or ≥ 140 mmHg
- Diastolic blood pressure < 45 mmHg or ≥ 90 mmHg
- Participants with QTcB > 450 msec or clinically significant abnormal rhythm findings on 12-lead ECG at screening
- Participants with one or more of the following results in clinical laboratory tests conducted during screening, including additional tests:
- AST (SGOT) or ALT (SGPT) > 1.5 x the upper limit of the normal range
- Estimated glomerular filtration rate (eGFR, CKD-EPI equation) < 90 mL/min/1.73m²
- Blood platelet count < 130,000/μL, PT INR > 1.2, or aPTT > 36.4 sec
- Participants who have taken any prescription drug or herbal medicine within 2 weeks prior to the scheduled date of the first administration of the investigational product, or any OTC drug, health functional food including liver function supplements, or vitamin preparation within 1 week prior to the scheduled date of the first administration of the investigational product (however, participants may be enrolled if other conditions are deemed reasonable by the investigator), or who are expected to take any such product
- Participants who have taken drug-metabolizing enzyme-inducing drugs, such as barbiturates, or drug metabolism-inhibiting drugs, such as clarithromycin, within 1 month prior to the scheduled date of the first administration of the investigational product
- Participants who have participated in another clinical trial (including a bioequivalence trial) and received an investigational product within 6 months prior to the scheduled date of the first administration of the investigational product
- Participants who have donated whole blood within 2 months, or who have donated blood components or received a blood transfusion within 1 month prior to the scheduled date of the first administration of the investigational product.
- Participants (however, participants who stopped smoking at least 3 months prior to the scheduled date of the first administration of the investigational product may be enrolled), or heavy smokers (10 cigarettes/day), or participants who are unable to abstain from smoking until the end of the clinical trial
- Participants who regularly consume alcohol (>21 units/week; 1 unit = 10 g of pure alcohol) or are unable to abstain from alcohol from 3 days prior to the scheduled date of the first administration of the investigational product until the end of the clinical trial
- Participants who have regularly consumed excessive caffeine (>5 units/day; 1 unit = 80 mg of caffeine) or are unable to refrain from consuming caffeine-containing foods or beverages (e.g., coffee, tea (including black tea and green tea), carbonated beverages, coffee beverages, coffee milk, tonic drinks, and energy drinks) from 3 days prior to the scheduled date of the first administration of the investigational product until the end of the clinical trial
- Participants who have consumed or are unable to refrain from consuming grapefruit, grapefruit juice, or grapefruit-containing foods from 3 days prior to the scheduled date of the first administration of the investigational product until the end of the clinical trial
- Participants who have unusual dietary habits (e.g., consumption of ≥1 L of grapefruit juice per day) or are unable to consume the standardized diet provided by the Clinical Trials Center during the inpatient period
- Participants who, or whose spouse or partner, are unable to use a contraceptive method considered highly effective throughout the entire clinical trial and for at least 4 weeks after the last administration of the investigational product, and participants who do not agree not to donate sperm during that period
- [Contraceptive Methods Considered Highly Effective]
- Intrauterine device, intrauterine hormone-releasing system
- Bilateral tubal occlusion
- Sexual abstinence, only when defined as refraining from heterosexual intercourse throughout the entire period of risk.
- Participants determined by the investigator to be unsuitable for participation in this clinical trial for reasons other than those listed above.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
South Korea1 site
Seoul National University Hospital, Clinical Trial Center
Seoul
Seung Hwan Lee, MD, PhD, +82 2-2072-2343, leejh413@snu.ac.kr
About this study
Official title: An Open-label, Single-sequence, 3-periods, 3-treatments, Phase I Clinical Trial to Evaluate the Pharmacokinetic/Pharmacodynamic Drug-drug Interaction and Safety/Tolerability Between Tegoprazan and Aspirin in Healthy Male Adult Volunteers
This Clinical Trial Aims to Evaluate the PK/PD Drug-Drug Interaction and Safety/Tolerability of Tegoprazan and Aspirin in Healthy Adult Male Volunteers.
Read the detailed description
Trial Objective
- Primary Objective
- To evaluate the effect of Tegoprazan on the PK and PD of Aspirin following coadministration of Tegoprazan and Aspirin in healthy male adult participants.
- To evaluate the effect of Aspirin on the PK of Tegoprazan following coadministration of Tegoprazan and Aspirin in healthy male adult participants.
- Secondary Objective
- To evaluate the safety and tolerability of Tegoprazan and Aspirin when coadministered in healthy male adult participants.
- Exploratory Objective
- To perform an exploratory evaluation of the concentrations and interconversion characteristics of isomers(R-form and S-form) in blood to explore the in vivo biotransformation profile of Tegoprazan and its metabolites in healthy male adult participants.
- Conditions
- Healthy Adult Male
- Being tested
- Aspirin, Tegoprazan, Tegoprazan + Aspirin
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AspirinDrug
Also called Aspirin Protect Tab. 100 mg
QD, for 5 days
TegoprazanDrug
Also called K-CAB Tab. 50 mg
QD, for 5 days
Tegoprazan + AspirinDrug
QD, for 5 days
| Study group | Role | What they receive |
|---|---|---|
| Aspirin-Tegoprazan Sequence | Experimental | Period 1 (Day 1-Day 5): Participants receive aspirin 100 mg
Period 2 (Day 16-Day 20): Participants receive tegoprazan 50 mg
Period 3 (Day 21-Day 25): Participants receive tegoprazan 50 mg and aspirin 100 mg Receives: Drug: Aspirin; Drug: Tegoprazan; Drug: Tegoprazan + Aspirin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cmax,ss of Aspirin
PK parameter of Aspirin
Measured: Day 1-Day 5, Day 22-Day 25 up to 24 hours
AUCtau,ss of Aspirin
PK parameter of Aspirin
Measured: Day 1-Day 5, Day 22-Day 25 up to 24 hours
Cmax,ss of Tegoprazan
PK parameter of Tegoprazan
Measured: Day 16-Day 20, Day 22-Day 25 up to 24 hours
AUCtau,ss of Tegoprazan
PK parameter of Tegoprazan
Measured: Day 16-Day 20, Day 22-Day 25 up to 24 hours
Inhibition of Platelet Aggregation (%)
PD parameter of Aspirin
Measured: Predose on Day 1 and 24 hours after the Day 5 dose; and predose on Day 21 and 24 hours after the Day 25 dose
Inhibition of Thromboxane B2 (%)
PD parameter of Aspirin
Measured: Predose on Day 1 and 24 hours after the Day 5 dose; and predose on Day 21 and 24 hours after the Day 25 dose
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2026
- Study start14 Oct 2026 (estimated)
- Primary completion31 Jan 2027 (estimated)
- Study completion30 Apr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy Adult MaleStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 34 participants (estimated)
Sponsor and investigators
- Lead sponsor
- HK inno.N Corporation
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- SeungHwan Lee, Principal investigator, Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07853248
- Sponsor's protocol ID
- IN_APA_122
- Status last verified
- Sep 2026
- First submitted
- 14 Sep 2026
- Last updated
- 1 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No